Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…ms to identify AS events associated with clinical benefits from immune checkpoint inhibitors and targeted therapies in mRCC.Materials and methods We conduct…
…trials revealed that CTHRC1(+) CAFs are linked to resistance to immune checkpoint inhibitors in MSI and MSS tumours, suggesting therapeutic potential for co…
…tical determinant of therapeutic immunity, shaping responses to immune checkpoint inhibitors, adoptive cellular therapies, and radiotherapy (RT). Interest h…
…Background Immune checkpoint inhibitors have improved outcomes for several malignancies; however, there…
…on of these biomarkers with the prognosis of patients receiving immune checkpoint inhibitors (ICIs) is not fully understood.Aim and Objectives The objective…
…en associated with poor outcomes. Current treatments, including immune checkpoint inhibitors, show limited efficacy in advanced disease. Compared with cutan…
…Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, offering durable res…
…Immune checkpoint inhibitors combined with platinum-based chemotherapy have become the first…
…l lung cancer (NSCLC), and its potential impact on responses to immune checkpoint inhibitors. This commentary examines several biological factors that may c…
…d microRNAs from 79 patients with metastatic NSCLC treated with immune checkpoint inhibitors (ICIs). High-dimensional omics data were integrated using Multi…
…, aggressive variant with rapid progression and poor prognosis. Immune checkpoint inhibitors, alone or combined with vascular endothelial growth factor-targ…
…tely diagnosed with bilateral epididymo-orchitis (EO) following pembrolizumab maintenance treatment. Our report adds to the three identified …